 TherapeuticsMD Inc NASDAQ: TXMD reported a Q1 EPS loss of 0.11 better than the analyst consensus estimate loss of 0.12, as well as an improvement from EPS loss of 0.21 a year ago. Sales of 19.90 million were slightly better than the consensus of 19.77 million. 